Online Office System

Journal Online

    column
    Post-translational modifications of proteins and cancer immunotherapy
    JIN Jing, JI Ming, CHEN Xiao-guang
    2019, 54(10):1711-1717. DOI:10.16438/j.0513-4870.2019-0695
    Abstract PDF
    Research progress of tumor immune and tumor metabolic drug targets
    LIU Jin-yi, REN Li-wen, LI Sha, TANG Qin, LI Wan, ZHENG Xiang-jin, WANG Jin-hua, DU Guan-hua
    2019, 54(10):1718-1727. DOI:10.16438/j.0513-4870.2019-0581
    Abstract PDF
    The mechanism and research progress of drug resistance of PD-1/PD-L1 immunotherapy in tumors
    YAN Shi-jia, SUN Lei, WAN Guo-hui
    2019, 54(10):1728-1734. DOI:10.16438/j.0513-4870.2019-0579
    Abstract PDF
    Advances in hyperprogressive disease of PD-1/PD-L1 antibody drugs and rational drug therapy
    YUAN Si-chen, ZHAO Hui-feng, WU Hao-shu, CAO Ji
    2019, 54(10):1735-1740. DOI:10.16438/j.0513-4870.2019-0569
    Abstract PDF
    Mechanistic advancement in chemotherapeutic agents modulated antitumor immune response
    XU Jun, GENG Mei-yu, HUANG Min
    2019, 54(10):1741-1748. DOI:10.16438/j.0513-4870.2019-0617
    Abstract PDF
    Review on clinical research progress of immunotherapy in liver cancer
    YAN Shi-jia, LIU Xian-ya, WAN Guo-hui
    2019, 54(10):1749-1754. DOI:10.16438/j.0513-4870.2019-0585
    Abstract PDF
    Mechanisms of metabolite-triggered oncogenic signaling in cancer
    WANG Xiao-min, HUANG Min
    2019, 54(10):1755-1770. DOI:10.16438/j.0513-4870.2019-0543
    Abstract PDF
    The roles of m6A in cancer biology and its targeted therapy
    PENG Yan-xi, DU Jun, WANG Hong-sheng
    2019, 54(10):1771-1782. DOI:10.16438/j.0513-4870.2019-0524
    Abstract PDF
    Non-coding RNA and tumor immune regulation
    GUO Qiao-ru, LIU Yun, SU Chao-yue, WANG Hui, ZHANG Jian-ye
    2019, 54(10):1783-1791. DOI:10.16438/j.0513-4870.2019-0570
    Abstract PDF
    Research progress in immunotherapy for glioblastoma
    L� Ying-qi, CHEN Yao-xing, WEI Chen-xuan, JIANG Gan, GAO Xiao-ling
    2019, 54(10):1792-1801. DOI:10.16438/j.0513-4870.2019-0572
    Abstract PDF
    Advances of microenvironment-activated nanosized drug delivery system for cancer immunotherapy
    HOU Bo, WANG Dang-ge, GAO Jing, WANG Hui, LI Ya-ping, YU Hai-jun
    2019, 54(10):1802-1809. DOI:10.16438/j.0513-4870.2019-0560
    Abstract PDF
    Advanced research and technology development of antibody-drug conjugates
    SONG Hong-bin, LIU Dong-lian, LI Peng-fei, ZHAO Ji-dong, QU Yan-fei
    2019, 54(10):1810-1817. DOI:10.16438/j.0513-4870.2019-0563
    Abstract PDF
    Research progress of dendritic cells anti-tumor vaccine stimulated by mRNA
    ZHAO Xing, GU Yang-zhuo, SONG Xiang-rong
    2019, 54(10):1818-1823. DOI:10.16438/j.0513-4870.2019-0648
    Abstract PDF
    Research progress of carnitine palmitoyltransferase 1 in tumor immunotherapy
    ZHANG Ming-yi, DU Ting-ting, JI Ming, CHEN Xiao-guang
    2019, 54(10):1824-1830. DOI:10.16438/j.0513-4870.2019-0689
    Abstract PDF
    Research advancement of succinyl-CoA transferase SCOT in tumor metabolism
    ZHANG Zhi-hui, WANG Qing-hua, JI Ming, CHEN Xiao-guang
    2019, 54(10):1831-1836. DOI:10.16438/j.0513-4870.2019-0671
    Abstract PDF
    Construction and anti-tumor efficacy of a peptide vaccine that targets calcium-binding protein S100A9
    LU Wu-guang, CAO Meng, SANG Ming, CAI Hua-man, CAO Peng, LI Rong-xiu
    2019, 54(10):1837-1844. DOI:10.16438/j.0513-4870.2019-0591
    Abstract PDF
    DEPTOR improves cisplatin chemosensitivity in esophageal squamous cell carcinoma cells by inducing Caspase-1-mediated pyroptosis
    DUAN Jing-jing, XU Hui-xin, LUO Pu, PAN Wen-jun, DONG Xiao-ying, ZHENG Hang
    2019, 54(10):1845-1850. DOI:10.16438/j.0513-4870.2019-0672
    Abstract PDF
    The antitumor activity of STAT3 target inhibitor Bt354 and molecular mechanism of anti-prostate cancer
    WANG Yu-chen, CHEN Yue, JI Ming, XUE Ni-na, CHEN Xiao-guang
    2019, 54(10):1851-1857. DOI:10.16438/j.0513-4870.2019-0668
    Abstract PDF
    The optimization and application of cell-based screening model for IL-17-mediated signaling pathway
    XUE Ni-na, JI Ming, ZHANG Ming-yi, LIU Yi-chen, CHEN Xiao-guang
    2019, 54(10):1858-1862. DOI:10.16438/j.0513-4870.2019-0703
    Abstract PDF
    The effects of different stimulators on the activation of human lymphocytes
    YAN Zheng, XUE Ni-na, JI Ming, LAI Fang-fang, CHEN Xiao-guang
    2019, 54(10):1863-1867. DOI:10.16438/j.0513-4870.2019-0670
    Abstract PDF
    Establishment and optimization of an enzyme-cell based high-throughput screening platform for IDO1 inhibitors
    LAI Fang-fang, XUE Ni-na, JI Ming, DU Ting-ting, LI Ling, SHENG Li, CHEN Xiao-guang
    2019, 54(10):1868-1874. DOI:10.16438/j.0513-4870.2019-0697
    Abstract PDF
    Establishment and application of STING agonist in-vitro screening model
    WANG Ming-jin, FU Rong, JIANG Hui-min, JIN Jing, CHEN Xiao-guang
    2019, 54(10):1875-1880. DOI:10.16438/j.0513-4870.2019-0735
    Abstract PDF

    Recommend